Sie sind hier: Forschung > Core Technologies > Virale Vector Core

Virale Vector Core

Viral vector core

Recombinant viral vectors are capable of achieving long-term and efficient transgene expression in cells and model organisms. The core facility aims to provide state-of-the-art viral vector technology to investigators for basic science research. We provide high-titer high-quality research grade adenoviruses, adeno-associated viruses (AAV) and retroviruses that can be used for both in vitro and in vivo applications. In addition, we offer consultation on strategy and choice of viral vector (serotype) and also design and production of custom vector tailored to the specific needs of the investigator. Virus stock production takes about 4-6 weeks.

Adeno-associated virus (AAV)

Adeno-associated virus is currently the most widely used viral vector for gene therapy. AAV vectors allow for persistent transgene expression and low toxicity in model organisms both in vitro and in vivo.

AAV vectors carry a payload of up to 4.5 kb and can be packaged into different serotypes (AAV1, 2, 3, 4, 5, 6, 7, 8, 9,10 and 11). All AAV preparations are purified by iodixanol gradient ultracentrifugation and are concentrated to titers ranging from 1012-1014 Vg/mL. On request, purity of AAV preparations can also be assayed for proportion of viral capsid proteins by subjecting virus preparations to polyacrylamide gel electrophoresis and silver staining

Moloney murine leukemia virus (MMLV)

MMLV, a type of retrovirus, is the most efficient vehicle for permanent gene modifications in mammalian cells. MMLV efficiently infects only dividing cells. Our lab has recently developed a MMLV-based strategy to transduce non-myocyte cells within the heart. MMLV preparations are concentrated and purified using ultracentrifugation to titers ranging from 1010-1012 Vg/mL.